OASIS-1 Trial: A Plain-English Overview of What It Established

At a glance

| Detail | Value | |---|---| | Trial name | OASIS-1 (Oral Semaglutide for Adults with Obesity or Overweight) | | N | 667 | | Intervention | Oral semaglutide 50 mg once daily | | Comparator | Matching placebo | | Duration | 68 weeks | | Primary endpoint | Percentage change in body weight from baseline | | Key result | −15.1% (semaglutide) vs −2.4% (placebo); estimated treatment difference −12.7 percentage points | | Publication | The Lancet, 2023 |

Why This Trial Exists

Before OASIS-1, semaglutide had already proven itself a potent weight-loss drug, but only through subcutaneous injection. The STEP program established that injectable semaglutide 2.4 mg (branded as Wegovy) could produce roughly 15% to 17% weight reduction. A lower-dose oral formulation (Rybelsus, 7 mg and 14 mg) was approved for type 2 diabetes, yet those doses were too low to move the needle meaningfully on body weight in people without diabetes.

The obvious question: could a higher oral dose close the gap with the injection? OASIS-1 was designed to answer exactly that, using a new 50 mg oral tablet, more than three times the highest previously approved oral dose. If it worked, millions of patients who resist or cannot tolerate injections would have a pill-based alternative for clinically significant weight management.

Who Was Enrolled

OASIS-1 recruited adults aged 18 and older with a BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. Participants did not have type 2 diabetes, a deliberate choice to isolate weight-loss efficacy from glucose-lowering confounders.

Key demographic details from the published trial:

• Mean age: approximately 48 years
• Mean baseline BMI: approximately 37 kg/m²
• Mean baseline body weight: approximately 105 kg
• Women comprised roughly 78% of participants
• The trial enrolled across 28 sites in multiple countries

Exclusion criteria filtered out individuals with a history of pancreatitis, medullary thyroid carcinoma or MEN2 syndrome, prior bariatric surgery, or use of other weight-loss medications within 90 days. These exclusions mirror the FDA labeling warnings for semaglutide products.

What Participants Were Given

Randomization was 1:1. The 334 participants in the active arm received oral semaglutide with a dose-escalation protocol: starting at 3 mg daily for 4 weeks, stepping up to 7 mg, then 14 mg, then 25 mg, and finally reaching the target dose of 50 mg by week 16. The 333 participants in the placebo arm followed the same escalation schedule with matching inactive tablets. Both groups received standardized lifestyle counseling (reduced-calorie diet and increased physical activity).

The escalation mattered. GLP-1 receptor agonists are notorious for gastrointestinal side effects, particularly nausea, during initiation. Gradual dose escalation gives the gut time to adapt. Even so, the 50 mg dose is a large pharmacologic load delivered orally, and the trial carefully tracked tolerability at each step.

All tablets had to be taken on an empty stomach with no more than 120 mL (about half a cup) of plain water, at least 30 minutes before any food, drink, or other oral medications. This fasting requirement exists because food dramatically reduces oral semaglutide absorption. It is the same instruction that applies to the lower-dose Rybelsus formulation.

What Was Measured

OASIS-1 used two co-primary endpoints, a design choice borrowed from the STEP trials:

1. Percentage change in body weight from baseline to week 68 (treatment policy estimand, meaning all randomized participants are included regardless of whether they stayed on drug)
2. Proportion of participants achieving ≥5% body weight reduction at week 68

The treatment policy estimand is the more conservative of the two statistical approaches because it counts dropouts and non-completers in the denominator. The trial also reported a "trial product estimand" that reflects outcomes in participants who stayed on treatment, but regulatory agencies and skeptical clinicians rightly focus on the intention-to-treat numbers.

Secondary endpoints included the proportion losing ≥10%, ≥15%, and ≥20% of body weight, change in waist circumference, and changes in cardiometabolic biomarkers (blood pressure, lipids, C-reactive protein, HbA1c).

What the Trial Found

Weight Loss

The headline numbers from the primary publication:

| Outcome | Oral semaglutide 50 mg | Placebo | Estimated treatment difference | |---|---|---|---| | Mean % weight change (treatment policy) | −15.1% | −2.4% | −12.7 pp (p <0.0001) | | Mean % weight change (on-treatment) | −17.4% | −1.8% | −15.6 pp | | ≥5% weight loss | 84.9% | 25.8% |, | | ≥10% weight loss | 69.0% | 12.0% |, | | ≥15% weight loss | 53.5% | 6.0% |, | | ≥20% weight loss | 33.9% | 3.0% |, |

These results are striking. More than half of participants on the active drug lost at least 15% of their body weight with a pill alone. For context, bariatric surgery typically produces 20% to 35% weight loss at one year depending on the procedure, so oral semaglutide 50 mg lands in the range where meaningful metabolic improvements are expected.

Cardiometabolic Improvements

Weight loss of this magnitude predictably improved metabolic markers. The semaglutide group showed reductions in waist circumference, systolic blood pressure, triglycerides, and C-reactive protein compared to placebo. HbA1c also dropped, despite this being a non-diabetic population, suggesting improved insulin sensitivity across the cohort.

Adverse Events and Tolerability

Gastrointestinal side effects were the dominant safety signal, consistent with every prior semaglutide trial:

| Adverse event | Semaglutide 50 mg | Placebo | |---|---|---| | Nausea | 35.8% | 7.2% | | Vomiting | 15.9% | 2.4% | | Diarrhea | 17.4% | 7.5% | | Constipation | 15.3% | 4.5% | | Discontinuation due to AEs | 14.0% | 3.6% |

The 14% discontinuation rate in the semaglutide arm is higher than the roughly 7% reported in the STEP-1 trial of injectable semaglutide 2.4 mg. This gap likely reflects the higher peak-to-trough variability of oral dosing compared with steady-state subcutaneous delivery. Most GI events occurred during dose escalation and were mild to moderate in severity, but they were clearly a barrier for a meaningful minority.

No cases of pancreatitis, medullary thyroid carcinoma, or major adverse cardiovascular events were reported in the active arm, though the trial was not powered to detect rare safety signals.

Limitations the Authors Acknowledged

The trial had several honest limitations worth highlighting:

Short follow-up for a chronic disease. Sixty-eight weeks tells you what happens during treatment. It says nothing about durability after stopping. Data from STEP-1 extension studies showed that patients regain roughly two-thirds of lost weight within a year of discontinuing injectable semaglutide. There is no reason to assume the oral form behaves differently.

Homogeneous population. The majority of participants were White women. The trial was not designed to detect efficacy differences by race or ethnicity, and the results may not translate identically to underrepresented populations.

Exclusion of type 2 diabetes. Patients with diabetes were deliberately excluded. Separate trials (OASIS-2) addressed that population. Clinicians treating the many patients who have both obesity and diabetes should not directly extrapolate OASIS-1 results.

No active comparator. The trial compared oral semaglutide to placebo, not to injectable semaglutide or tirzepatide. Cross-trial comparisons suggest the 50 mg oral dose approximates injectable semaglutide 2.4 mg in efficacy, but head-to-head data did not exist at publication.

Fasting requirement burden. The strict empty-stomach protocol is difficult in practice. Patients who do not adhere to the fasting window may absorb less drug and achieve lower weight loss than trial participants, who were coached and monitored.

What This Means for Clinical Practice

OASIS-1 established proof of concept: a GLP-1 receptor agonist pill can produce weight loss comparable to current injectable options. That matters because needle aversion, injection fatigue, and cold-chain logistics are real barriers to treatment adherence in obesity care.

The 50 mg oral dose was not yet FDA-approved for weight management as of the trial's publication. Novo Nordisk submitted regulatory applications based on the OASIS program data, and the clinical community has been watching for approval decisions and pricing signals. If approved, the practical question becomes whether the fasting requirement and higher GI side-effect rate make the pill a first-line choice or a second option for patients who refuse injections.

Clinicians should also weigh OASIS-1 against the evolving competitive field. Tirzepatide (a dual GIP/GLP-1 agonist) has demonstrated even greater weight loss in its SURMOUNT trials, and multiple oral GLP-1 candidates from other manufacturers are in late-stage development. The era of effective oral anti-obesity medications is arriving, and OASIS-1 was its opening chapter.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once a day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10403):705-719. PubMed
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. PubMed
5. U.S. FDA. Rybelsus (semaglutide) tablets prescribing information. FDA Label